论文信息 - Reply to GASTRO-D-19-,01448, GASTRO-D-19-01576, GASTRO-D-19-02060, and GASTRO-D-19-02139. - 字舞流文

Reply to GASTRO-D-19-,01448, GASTRO-D-19-01576, GASTRO-D-19-02060, and GASTRO-D-19-02139.

S. Yusuf | P. Moayyedi | J. Eikelboom

[1] P. Moayyedi,et al. Interpreting Reported Risks Associated with Use of Proton Pump Inhibitors: Residual Confounding in a 10-Year Analysis of National Ambulatory Data. , 2020, Gastroenterology.

[2] Deepak L. Bhatt,et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. , 2019, Gastroenterology.

[3] Deepak L. Bhatt,et al. Pantoprazole to Prevents Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-blind, Placebo-controlled Trial. , 2019, Gastroenterology.

[4] P. Moayyedi,et al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial , 2018, The Lancet.

[5] P. Moayyedi,et al. ACG and CAG Clinical Guideline: Management of Dyspepsia , 2017, The American Journal of Gastroenterology.

[6] Josef Coresh,et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. , 2016, JAMA internal medicine.

[7] P. Moayyedi,et al. The risks of PPI therapy , 2012, Nature Reviews Gastroenterology &Hepatology.

[8] Yu-Xiao Yang,et al. Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.